— News and commentary from the endocrinology world
May 26, 2026
• 2 min read
Patients with obesity dropped a mean 28% of their body weight with a 12-mg dose of the investigational triple-receptor agonist retatrutide over 80 weeks in a phase III study, Eli Lilly announced. Nearly half had weight loss of 30% or greater, levels typically only seen with bariatric surgery.
There was little to no benefit from using calcium and/or vitamin D supplements to prevent fractures and falls, a systematic review and meta-analysis of 69 randomized trials found. (The BMJ)
